Rich human data
Tirzepatide
SURMOUNT-1 tested three once-weekly amounts over 72 weeks. The guide sets those trial figures beside the vial arithmetic they get quoted with.
Read the guideGuides
This is the section where each compound gets one page, and the page opens with the same question rather than the same promise: what does the published human record contain for this molecule, and what does it not contain. Thirty pages sit here, tiered by how much evidence exists rather than by what anyone hopes the compound does.
Short answer
What this section is: thirty pages that each take one compound or one comparison, report what named trials and approved labels state about it, and stop where the record stops.
How it is tiered: three compounds carry large registrational programs with published figures, two carry a thin early human record, four have been studied almost entirely in animals, and one is a blend that has never been tested as a blend.
What sits alongside the compounds: the bacteriostatic water pages, the route and injection-site pages, and the head-to-head comparisons, because nearly every guide runs into all three.
What none of them do: pick an amount for a reader. Numbers appear as what a named trial tested or what an approved label prints, and nothing here turns that into a suggestion.
Because the shape of an honest answer changes depending on whether a human trial exists at all, and a goal-based grouping hides exactly that difference behind an outcome word.
The split it produces: tirzepatide, semaglutide and tesamorelin come with phase 3 programs, published endpoints and approved labels. BPC-157, TB-500, MOTS-c and GHK-Cu do not have a completed randomized human trial between them on the form people buy.
Why that ordering matters: a page grouped under fat loss or recovery reads as though the four compounds under it are four options for the same job. Grouped by evidence, the first thing visible is that one of them has 72-week outcome data and another has rodents.
The same four moves, in the same order: what the molecule is, what named trials tested and reported, the arithmetic that joins a milligram figure on a label to a reading on a barrel, and an explicit statement of what the record does not cover.
Figures keep their conditions: a result is reported with its arm, its timepoint and its population attached, and figures from separate trials are never set side by side as though one experiment produced both.
An empty record is reported as empty: where no human trial exists, the guide says so and leaves the gap visible rather than filling it with a number that circulates online without an origin.
The Decadewise briefing
One guide, one label read, or one worked comparison from this section, every week. Free.
Education only. Unsubscribe anytime.
Grouped by how much human evidence exists: the tier label on each card is the honest headline of the page behind it, not a rating of the compound.
Rich human data
SURMOUNT-1 tested three once-weekly amounts over 72 weeks. The guide sets those trial figures beside the vial arithmetic they get quoted with.
Read the guideRich human data
STEP 1 ran one maintenance level over 68 weeks behind a staged escalation, with the approved pen strengths printed next to it.
Read the guideRich human data
Two phase 3 trials, a daily rhythm rather than a weekly one, and one narrow approved indication.
Read the guideLimited human data
A small early human record dosed by bodyweight, a development program that stopped, and the two versions forum posts keep merging.
Read the guideLimited human data
Three published human studies, all old: a pharmacokinetics study, a phase 2 trial for postoperative ileus, and an intranasal study.
Read the guideResearch only
No completed randomized human trial, a large rodent record measured per kilogram, and thirty analyzed subjects across three uncontrolled pilots.
Read the guideResearch only
Every human figure in the record belongs to the parent molecule, thymosin beta-4, and not to the seven-amino-acid fragment sold under the name.
Read the guideResearch only
A mitochondrial peptide with a 2015 discovery paper, one completed trial of an analog, and a phase 2 trial recruiting with nothing public on its schedule.
Read the guideResearch only
The human record here is topical: a cream ulcer trial and post-laser skin care. The injectable lane has no human trial behind it at all.
Read the guideBlend decode
A four-compound blend with zero published studies on the blend itself. The guide decodes the components and reconciles the two reconstitution camps.
Read the guideSection hub
Ten Khavinson short peptides, each with what the retrieved record actually contains and what it does not. Most have no human data at all, and the pages say so.
Open the hubApproved drug
Afamelanotide is an approved 16mg implant. The guide separates that record from the weight-based injection studies and the units math.
Read the guideUnapproved
Every figure traced to a source, with the population it came from, what a 10mg vial assayed at, and the units math.
Read the guideComparison
One is an approved MC1R drug, the other an unapproved cyclic peptide. What actually separates them, sourced.
Read the guideNo human trial
What FDA's 2026 review found, the mouse and cell work behind it, and what a 0.1 percent cream actually holds.
Read the guideTrial record
The trial and label figures with route and population, and the units math by vial. SS-31 is elamipretide.
Read the guideNo human trial
What the studies gave and to which species, why no human trial exists, and the half-life claim checked against its source.
Read the guideBlend decode
What a 70mg vial holds, what the evidence says about each of the three peptides, and why this page prints no dosing chart.
Read the guideTrial record
A 2.8kg result at 12 weeks that missed its own significance test, and a 24-week trial whose primary endpoint was not met.
Read the guideThin literature
A seven-residue fragment of spadin, also written mini-spadin. One 2017 mouse paper carries nearly the whole record.
Read the guideNaming
Not rival products: FST-344 is the precursor and FS-315 the mature chain. The real split is 315 against 288.
Read the guideWater
The label definition, how much benzyl alcohol each presentation carries, and the single indication the label states for it.
Read the explainerComparison
One is water for injection with a preservative added, the other has nothing added. What the preservative buys is a multiple-dose container.
Read the comparisonComparison
Saline is salt water at the concentration of blood and bacteriostatic water carries no solute, so the two differ on tonicity first.
Read the comparisonLabel record
An approved label names one route for its own product and rules the others out. What the metabolic and depot labels each specify.
Read the explainerTrial record
The body regions the registered protocols allowed, and how a registry entry carries forward into the approved label.
Read the explainerLabel record
Gauge is a tubing size standardized in ISO 9626 and the number runs backwards. What the pen, vial and depot labels name for their own products.
Read the explainerComparison
Somatropin is a 191-amino-acid chain identical to the pituitary hormone. The shorter sequences it gets compared to act one step upstream of it.
Read the comparisonComparison
Nonsteroidal small molecules that bind the androgen receptor, against chains of amino acids: two chemical classes sharing one marketplace.
Read the comparisonComparison
SURPASS-2 put both in one protocol, one population and the same forty weeks, then reported every arm. What a single head-to-head cannot settle.
Read the comparisonEvery page is reviewed by medical professionals before it ships, and written with longtime biohackers who were doing this before it was a trend. Reviewed still does not mean prescribed: nothing here is medical advice. It is research, trial data, and reported use, with the numbers intact so you can check them. For decisions about your body, see a doctor who can look at your labs.
The weekly briefing
Get the next compound guide.
New trial reads, new label reads, and the arithmetic that goes with them. One clear email a week.
Education only, never medical advice. Unsubscribe anytime.